[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"renal-replacement-therapy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:renal-replacement-therapy":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,51,83,111,141,168,198,228,252],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":30,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100613110","epidemiology-and-processes-of-care-for-renal-replacement-therapy-in-acute-kidney-injury-in-latin-america-100613110",false,"NCT07262320","Epidemiology and Processes of Care for Renal Replacement Therapy in Acute Kidney Injury in Latin America","LATAM-AKID","Inclusion Criteria:\n\n* Adult patient (≥18) admitted to the ICU\n* First ICU admission during current hospitalization\n* Diagnosis of acute kidney injury stage 3 according to KDIGO guidelines\n* RRT initiated no earlier than 3 days before or no later than 7 days after ICU admission\n\nExclusion Criteria:\n\n* Transfer from outside hospital with ongoing RRT\n* RRT exposure of less than 2 days (if CRRT or PD was provided) or less than 2 HD\u002FSLED sessions\n* Kidney failure (ESRD) patients on maintenance dialysis\n* Kidney transplant recipients\n* Previous or new diagnosis of glomerulonephritis","ALL","18 Years",{"count":19,"type":20},1000,"ESTIMATED","OBSERVATIONAL","This is an international, multicenter, observational study aimed at investigating acute kidney injury requiring renal replacement therapy (AKI-RRT) in Latin American countries. The main questions this study aims to answer are:\n\n* What is the epidemiology, outcomes, and processes of care for patients with AKI-RRT in Latin America?\n* How do outcomes differ across different countries in Latin America?\n* What factors (demographics, clinical, socioeconomic) influence outcomes in patients with AKI-RRT in Latin America?\n\nThe main aims of this study are to:\n\n* Establish a comprehensive database containing clinical, laboratory, treatment, process, and outcome data of patients with AKI-RRT in Latin America\n* Describe current epidemiology of AKI-RRT in Latin America\n* Compare processes of care and outcomes across different countries in Latin America\n* Provide data resources to facilitate and promote clinical research in AKI-RRT",[24,25,26,27,28,29],"Dialysis","Critically Ill Acute Kidney Injury","Renal Replacement Therapy for Acute Kidney Injury in ICU","Acute Kidney Injury","Renal Replacement Therapy","AKI",[29,31,32,33,34,35,36,37],"ICU","RRT","Latin America","acute kidney injury","renal replacement therapy","intensive care unit","dialysis","RECRUITING","2026-03-11",{"date":41,"type":42},"2026-03-12","ACTUAL",{"date":44,"type":42},"2026-03-01",{"date":46,"type":20},"2027-06-30",{"name":48,"class":49},"University of Alabama at Birmingham","OTHER",15,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":57,"eligibilityCriteria":58,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":59,"targetDuration":4,"studyType":61,"phases":62,"briefSummary":64,"conditions":65,"keywords":67,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":82},"100519024","evaluation-of-integrated-versus-parallel-connection-for-renal-replacement-therapy-in-ecmo-patients-100519024","NCT06038162","Evaluation of Integrated Versus Parallel Connection for Renal Replacement Therapy in ECMO Patients","Evaluation of Integrated Versus Parallel Continuous Renal Replacement Therapy Connection in ECMO Patients: a Randomized Controlled Trial","EPIC-ECMO","Inclusion Criteria:\n\n* Patients aged above 18 years\n* Patient on VA-ECMO who requires the initiation of continuous RRT during VA-ECMO treatment\n* Patient with a foreseeable length of stay in intensive care greater than 24 hours\n\nExclusion Criteria:\n\n* Patient who does not have a vascular capital allowing for the insertion of a new dialysis catheter to administer RRT and therefore cannot be randomized to the parallel connection group\n* High pressures monitored on ECMO not allowing direct RRT catherter on ECMO\n* Pregnant, parturient, or breastfeeding women\n* Patient deprived of liberty by a judicial or administrative decision\n* Patient under psychiatric care\n* Patient subject to a legal protection measure (guardianship, curators)\n* Patient not affiliated to a social security system\n* Patient participating in another interventional research study in the field of extra purification renal",{"count":60,"type":20},158,"INTERVENTIONAL",[63],"NA","Extracorporeal membrane oxygenation (ECMO) is an extra-corporeal assistance used in case of respiratory or circulatory failure. In case of circulatory failure, ECMO is in the veno-arterial configuration (VA-ECMO). VA-ECMO patients are at high risk of developing acute kidney injury (AKI) and renal replacement therapy (RRT) may be needed in 50% of ECMO patients. Although the administration of RRT in ECMO patients has major implications, no specific recommendations are currently available. The 2020 Kidney Disease: Improving Global Outcomes (KDIGO) international conference identified the evaluation of RRT in these ECMO patients as a research priority.\n\nIn 2023, the two main configurations used to administer RRT in ECMO patients are an independent delivery on a separate vascular access (parallel connection) or an integration of the RRT machine directly into the ECMO circuit (integrated connection). The integrated connection may reduce infectious and bleeding complications associated with the use of a second vascular access. However, it can expose the hemofilter and circuit to excessive positive pressures that can trigger pressure alarms in the RRT machine and expose the patient to a theoretical risk of air embolism or hemolysis. Furthermore, there is currently no robust data comparing the hemofilter lifespan with the parallel or with the integrated connection, although the filter lifespan is a crucial parameter to assess the quality of the RRT delivery in the ICU. The investigators recently performed a survey of practices in this context of ECMO patients. The investigators found that both strategies (parallel and integrated connection) are widely used and can be seen as common patient care.\n\nThe hypothesis tested in this study is the following: when RRT is integrated to the ECMO circuit, the hemofilter lifespan is non inferior to the one when RRT is delivered on a separate vascular access. Only VA-ECMO patients will be enrolled in this trial.",[66,28,27],"Venoarterial Extracorporeal Membrane Oxygenation",[68,32,69,70,71,72],"VA-ECMO","connection","integrated","parallel","hemofilter","2026-01-16",{"date":75,"type":42},"2026-01-20",{"date":77,"type":42},"2024-02-07",{"date":79,"type":20},"2028-04-07",{"name":81,"class":49},"Hospices Civils de Lyon",12,{"id":84,"slug":85,"hasResults":11,"nctId":86,"briefTitle":87,"officialTitle":88,"acronym":89,"eligibilityCriteria":90,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":91,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":93,"conditions":94,"keywords":96,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":110},"100538002","analgesia-nociception-index-to-explore-autonomic-nervous-system-in-patients-with-continuous-renal-replacement-therapy-100538002","NCT06285162","Analgesia Nociception Index to Explore Autonomic Nervous System in Patients With Continuous Renal Replacement Therapy","Analgesia Nociception Index and Autonomic Nervous System Exploration During Continuous Renal Replacement Therapy in Intensive Care Patients.","UFANI","Inclusion Criteria:\n\n* Continuous renal replacement therapy in intensive care unit\n* Initiation of net ultrafiltration according to the protocol of the department or to EARLYDRY study (NCT 05817539) (3 criteria required):\n\n  * Fluid overload \\> 5% or peripheral oedema\n  * Noradrenaline equivalent \\\u003C0.5μg\u002Fkg\u002Fmin\n  * No peripheral hypoperfusion\n* Invasive blood pressure monitoring\n* Central venous line in superior vena cava territory\n* Regular sinus rhythm\n* Patient awake or Richmond Agitation and Sedation Scale \\> -3\n\nExclusion Criteria:\n\n* Ongoing administration of inotropes\n* Ongoing administration of beta blockers\n* Current administration of alpha-2 agonists\n* History of dysautonomia\n* Pregnant or breast-feeding woman\n* Mechanical circulatory assistance\n* Opposition to participate\n* Adults under legal protection\n* Persons deprived of their liberty by judicial or administrative decision",{"count":92,"type":20},30,"The Analgesia Nociception Index (ANI) reflects the balance between sympathetic and parasympathetic tone. It is based on a specific interpretation of the R-R interval variation. During fluid removal by net ultrafiltration in patients with fluid overload and continuous renal replacement therapy, some data suggest that haemodynamic variation could be induced by the autonomic nervous system. The study aims to investigate ANI variations in this context and their association with the haemodynamic variations observed.",[95,28],"Critically Ill",[97,98,99,100,101],"Analgesia Nociception Index","R-R interval","autonomic nervous system","haemodynamic","fluid removal","2026-01-14",{"date":104,"type":42},"2026-01-15",{"date":106,"type":42},"2026-01-09",{"date":108,"type":20},"2027-04",{"name":81,"class":49},1,{"id":112,"slug":113,"hasResults":11,"nctId":114,"briefTitle":115,"officialTitle":116,"acronym":117,"eligibilityCriteria":118,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":119,"targetDuration":121,"studyType":21,"phases":4,"briefSummary":122,"conditions":123,"keywords":127,"overallStatus":131,"whyStopped":4,"lastUpdateSubmitDate":132,"lastUpdatePostDateStruct":133,"startDateStruct":135,"completionDateStruct":137,"leadSponsor":139,"locationsCount":4},"100617000","machine-learning-and-artificial-intelligence-algorithms-to-optimize-the-performance-and-delivery-of-acute-dialysis-100617000","NCT07312929","Machine Learning and Artificial Intelligence Algorithms to Optimize the Performance and Delivery of Acute Dialysis","SMART DIALYSIS - Scaling Machine Learning and Artificial Intelligence AlgoRithms to OpTimize the Performance and Delivery of Acute DIALYSIS.","SMART DIALYSIS","Inclusion Criteria\n\nPatients admitted to an intensive care unit (ICU) who require acute renal replacement therapy, either intermittent or continuous.\n\nExclusion Criteria\n\nReceipt of renal replacement therapy for less than 24 hours.\n\nPre-existing end-stage kidney disease.",{"count":120,"type":20},7500,"90 Days","SMART DIALYSIS - Scaling Machine Learning and Artificial Intelligence AlgoRithms to OpTimize the Performance and Delivery of Acute DIALYSIS.\n\nHypothesis:\n\nCan the investigators develop and implement Machine Learning and Artificial Intelligence Algorithms into Clinical Information Systems to Optimize the Prescription, Delivery, and Performance of Acute Dialysis?\n\nObjective(s):\n\n1. Identify variables surrounding identified Key Performance Indicators that may be used by Machine Learning and Artificial Intelligence algorithms to optimize the prescription and performance of acute dialysis.\n2. Develop Machine Learning and Artificial Intelligence algorithms to help guide the prescription and delivery of acute dialysis in the development of Clinical Decision Support tools and Best Practice Advisories and create a ML\u002FAI Augmented SMART DIALYSIS Digital Dashboard.\n3. Implement and evaluate the performance of the developed Machine Learning and Artificial Intelligence algorithms on patient-centered and health economic outcomes.\n4. Validate and benchmark the performance of the evaluated Machine Learning and Artificial Intelligence algorithms across multiple jurisdictions.",[124,28,125,126],"Renal Dialysis","Renal Diseases","Quality Health Care",[24,128,129,130],"Articfical Inteligence","Key performance indicators","Machine Learning","NOT_YET_RECRUITING","2026-01-08",{"date":134,"type":42},"2026-01-12",{"date":136,"type":20},"2026-06-01",{"date":138,"type":20},"2031-06-30",{"name":140,"class":49},"University of Alberta",{"id":142,"slug":143,"hasResults":11,"nctId":144,"briefTitle":145,"officialTitle":146,"acronym":147,"eligibilityCriteria":148,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":149,"enrollmentInfo":150,"targetDuration":4,"studyType":61,"phases":151,"briefSummary":153,"conditions":154,"keywords":155,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":159,"lastUpdatePostDateStruct":160,"startDateStruct":162,"completionDateStruct":164,"leadSponsor":166,"locationsCount":110},"100311048","phase-2-effects-of-variation-of-sodium-dialysate-in-icu-100311048","NCT03329313","Effects of Variation of Sodium Dialysate in ICU","Effects of Variation of Sodium Dialysate in ICU Acute Kiney Injury","NADIRA","Inclusion criteria:\n\n* Age \\> 18 years old\n* Acute kidney injury requiring renal replacement therapy\n* Dialysis type: on line sustained low efficiency dialy dialysis -filtration\n* SOFA score \\> 5\n* Sodium serum level between 135 and 145mmol\u002Fl\n\nExclusion criteria:\n\n* Chronic kidney disease stade IV ou V\n* Obstrutive acute kidney injury\n* Renal tansplantation in the year before ICU admission\n* Moribund with risk of death in the 48 hours\n* Vulnerable persons or protected persons\n* Pregnant or breastfeeding mother","80 Years",{"count":60,"type":20},[152],"PHASE2","Intermittent hemodialysis\u002Fdiafiltration is a current renal replacement therapy (RRT) institued for ICU patients with AKI. For a better clinical tolerance, iinternational guidelines advise to use cold dialysate, increase duration session, decrease blood and dialysate flows, and increase level of sodium dialysate concentration (≥ 145mmol\u002Fl). Indeed, the use of a Na concentration dialysate \\> 145 mmol\u002Fl improves intradialytic hemodynamic tolerance but it may also induce fluid overload by the transfert of sodium from the dialysate compartment to the blood. Yet, fluid overload has been strongly associated with mortality in critically ills. The investigators hypothesized that the use of a level in sodium dialysate at 140 mmol\u002Fl with slow low efficiency daily dialysis-filtration (SLEDD-f) will permit a fair intradialytic hemodynamic tolerance without the adverse effect of intradiaclytic Na loading from the dialysate. Two randomized groups of ICU AKI patients treated by SLEDD-f will be compared in terms of intradialytic hemodynamic tolerance and overload accordong to 140 or 145 mmol\u002Fl of Na in the dialysate",[27,28],[156,157,158],"Intensive care unit","SLEDD-f","intermittent hemodialysis\u002Fdiafiltration","2025-09-24",{"date":161,"type":42},"2025-09-30",{"date":163,"type":42},"2018-04-19",{"date":165,"type":20},"2026-12-19",{"name":167,"class":49},"University Hospital, Montpellier",{"id":169,"slug":170,"hasResults":11,"nctId":171,"briefTitle":172,"officialTitle":173,"acronym":174,"eligibilityCriteria":175,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":176,"targetDuration":4,"studyType":61,"phases":178,"briefSummary":180,"conditions":181,"keywords":184,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":188,"lastUpdatePostDateStruct":189,"startDateStruct":191,"completionDateStruct":193,"leadSponsor":195,"locationsCount":197},"100416686","phase-4-albumin-to-enhance-recovery-after-acute-kidney-injury-100416686","NCT04705896","Albumin To Enhance Recovery After Acute Kidney Injury","Albumin To Enhance Recovery After Acute Kidney Injury: A Multi-Centre, Randomized, Controlled Trial","ALTER-AKI","Inclusion Criteria:\n\n* Age ≥18 years old;\n* Admission to a critical care unit\u002Fintensive care unit (ICU) for \\> 24 hours;\n* Receiving vasoactive therapy AND\u002FOR undergoing mechanical ventilation (including non-invasive mechanical ventilation (NIMV));\n* Immediate initiation of RRT for management of AKI is planned OR additional RRT sessions are imminently planned for patients who already received RRT during their ICU admission;\n\nExclusion Criteria:\n\n* Initiation of RRT for reasons other than AKI (e.g. drug intoxication, hypothermia) ;\n* Known pre-hospitalization end-stage kidney disease;\n* Kidney transplant within the past 365 days;\n* Presence or clinical suspicion of renal obstruction, rapidly progressive glomerulonephritis, vasculitis, thrombotic microangiopathy or acute interstitial nephritis;\n* Advanced cirrhosis (Child Pugh class C \\[score 10-15\\]), spontaneous bacterial peritonitis or hepatorenal syndrome;\n* Acute peritoneal dialysis used as the initial RRT modality;\n* Contraindications to albumin:\n\n  1. Admitted with traumatic brain injury\n  2. Increased intra-cranial pressure in those with intra-cranial pressure monitoring\n  3. Prior history of anaphylaxis to intravenous albumin\n  4. Contraindication or known objection to albumin\u002Fblood product transfusions\n* Already received 2 or more RRT sessions during ICU admission.\n* Limitations of medical therapy precluding RRT\u002Fmechanical ventilation\u002Fvasoactive medications or plan to transition to palliation",{"count":177,"type":20},856,[179],"PHASE4","Study objectives:\n\nTo determine whether, in critically ill patients with Acute Kidney Injury requiring renal replacement therapy (AKI-RRT), randomization to receive intravenous hyperoncotic albumin 20-25% (100 mL X two doses) compared to control\u002Fplacebo normal saline boluses (100 mL X two doses) given during RRT sessions, leads to:\n\n1. An increase in organ support-free days (primary outcome) at 28 days following randomization; and\n2. An increase in RRT-free days (principal secondary outcome) at 28 days following randomization.",[27,28,182,183],"Hypotension","Critical Illness",[185,186,24,187],"Albumin","Normal Saline","Intensive Care Unit","2025-04-30",{"date":190,"type":42},"2025-05-01",{"date":192,"type":42},"2023-11-02",{"date":194,"type":20},"2025-10-23",{"name":196,"class":49},"Ottawa Hospital Research Institute",16,{"id":199,"slug":200,"hasResults":11,"nctId":201,"briefTitle":202,"officialTitle":202,"acronym":4,"eligibilityCriteria":203,"healthyVolunteers":11,"sex":16,"minAge":204,"maxAge":4,"enrollmentInfo":205,"targetDuration":4,"studyType":61,"phases":207,"briefSummary":208,"conditions":209,"keywords":211,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":218,"lastUpdatePostDateStruct":219,"startDateStruct":221,"completionDateStruct":223,"leadSponsor":225,"locationsCount":110},"100568756","the-cost-effectiveness-of-artificial-intelligence-acute-kidney-injury-prediction-auxiliary-software-acura-aki-100568756","NCT06685367","The Cost-effectiveness of Artificial Intelligence Acute Kidney Injury Prediction Auxiliary Software (Acura AKI)","Inclusion Criteria:\n\n* Over 20 years old\n* Admitted to adult ICU\n* Hospital stay of more than 30 hours\n\nExclusion Criteria:\n\n* Known to have acute kidney injury at enrollment\n* Currently undergoing hemodialysis treatment\n* No available blood or urine test data\n* Pregnant women\n* HIV-positive patients\n* Those who have not provided informed consent form\n* Regarded as unsuitable for inclusion in the trial by the researcher","20 Years",{"count":206,"type":20},3600,[63],"\"Huede\" AI Aided AKI Prediction Software, Acura AKI, uses machine learning algorithms to predict the risk of AKI within the next 24 hours and provide a ranking of feature importance. By using Acura AKI, physicians can assess the risk of AKI, focusing on high-risk patients to provide care decisions. This study will be conducted in a prospective randomized clinical trial in adult ICUs, implementing the Acura AKI system for predicting AKI. The study aims to determine whether early prediction and intervention using the Acura AKI system can improve the outcomes of critically ill patients with adverse kidney conditions. The study endpoint is to evaluate the cost-effectiveness of using Acura AKI, including the incidence of AKI, dialysis rates, mortality rates, length of hospital stay, and treatment costs.",[27,210,28],"Intensive Care",[27,212,213,214,215,130,216,24,28,217],"Intensive Care Units","Critical Ill","Prevention","Artificial Intelligence","Clinical Decision Support System","Cost-effectiveness","2024-11-10",{"date":220,"type":42},"2024-11-12",{"date":222,"type":42},"2024-10-17",{"date":224,"type":20},"2025-09-15",{"name":226,"class":227},"Huede Healthtech Co., Ltd.","INDUSTRY",{"id":229,"slug":230,"hasResults":11,"nctId":231,"briefTitle":232,"officialTitle":232,"acronym":233,"eligibilityCriteria":234,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":235,"targetDuration":4,"studyType":61,"phases":237,"briefSummary":238,"conditions":239,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":243,"lastUpdatePostDateStruct":244,"startDateStruct":246,"completionDateStruct":248,"leadSponsor":250,"locationsCount":110},"100533486","aminoglycoside-administration-in-septic-patients-100533486","NCT06226441","Aminoglycoside Administration in Septic Patients","AMASEP","Inclusion Criteria:\n\n* age \\>18 years\n* diagnosis of sepsis or septic shock based on established criteria (Sepsis-3) 29\n* patients with GFR \\\u003C40 ml\u002Fmin\n* microbiemia from a Gram-negative microorganism and for which the attending physician decides to receive an aminoglycoside or sepsis\u002Fseptic shock for which it is decided to administer it\n* signed consent of the patients' next of kin\n\nExclusion Criteria:\n\n* absence of consent\n* known allergic reaction to aminoglycosides\n* infection from strains resistant to aminoglycosides. As long as the patient has received an aminoglycoside (empirical regimen) and the antibiogram follows it, the treatment can be modified based on the judgment of the attending physician, but the patient's data for the time he received the treatment under consideration are recorded and evaluated\n* unattainable placement of a central venous line for renal replacement therapy",{"count":236,"type":20},50,[63],"Sepsis is one of the main causes of mortality and morbidity in an ICU setting, while the responsible microorganisms most frequently isolated are multidrug-resistant gram-negative bacteria. Aminoglycoseides (AG) seem to be particularly effective in dealing with these microbes, however their potential toxicity, especially nephrotoxicity, often makes them an unsuitable treatment option. This becomes particularly evident in patients with already impaired renal function, a common occurrence in septic patients requiring ICU treatment. AG are bacteriocidal antibiotics the efficiency of which depends on the maximum concentration in patients' serum (Cpeak).\n\nPathophysiological changes in critically ill patients, result in significant distribution of the drug extravascullary resulting in a decreased concentration of the biologically active component. On the other hand, impaired renal clearance results in high serum drug levels (C trough) making the desired once-daily administration not always achieved.\n\nThe purpose of this study is to test the hypothesis of successful clearance of AG after achieving satisfactory serum levels and therefore their maximum effect minimizing potential toxicity, by using continuous veno-venous haemodiafiltration in patients with sepsis or septic shock and impaired renal function. This way, the aforementioned antibiotics could become a more frequent and potentially earlier choice for physicians in the treatment of sepsis and septic shock patients from multidrug-resistant microbes.",[240,241,242,28],"Sepsis","Septic Shock","Aminoglycoside Toxicity","2024-01-17",{"date":245,"type":42},"2024-01-26",{"date":247,"type":42},"2023-06-02",{"date":249,"type":20},"2026-12",{"name":251,"class":49},"University of Thessaly",{"id":253,"slug":254,"hasResults":11,"nctId":255,"briefTitle":256,"officialTitle":257,"acronym":258,"eligibilityCriteria":259,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":260,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":262,"conditions":263,"keywords":264,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":267,"lastUpdatePostDateStruct":268,"startDateStruct":270,"completionDateStruct":272,"leadSponsor":274,"locationsCount":110},"100334599","pharmacokinetics-of-antibiotics-in-patients-undergoing-renal-replacement-therapies-100334599","NCT03636464","Pharmacokinetics of Antibiotics in Patients Undergoing Renal Replacement Therapies","Pharmacokinetics and Deposition of Commonly Prescribed Antibiotics in Hospitalized Critically Ill Patients Undergoing Renal Replacement Therapies","RRTdose","Inclusion Criteria:\n\n* Adults \\> 18 year old\n* Prescribed meropenem, ertapenem, cefepime, colistin, Ceftazidime\u002FAvibactam , Ceftolozane\u002FTazobactam , or piperacillin\u002Ftazobactam for treatment of infection as part of standard medical care\n* Administered meropenem, ertapenem, cefepime, colistin, Ceftazidime\u002FAvibactam , Ceftolozane\u002FTazobactam ,or piperacillin\u002Ftazobactam while on renal replacement therapy (IHD or CRRT) or renal replacement therapy started while on any of these antibiotics\n* Patients with hemoglobin \\> 70 g\u002FL without blood transfusion in the past 24 hours\n* Informed consent given by patient, next of kin or legally authorized representative\n\nExclusion Criteria:\n\n* Less than 18 years of age\n* Pregnant females\n* Body mass index \\\u003C 18 or \\> 35 kg\u002Fm2\n* Presence of anemia (defined as hemoglobin \\\u003C 70 g\u002FL), thrombocytopenia, or leukopenia as defined by hematocrit, platelet, or white blood cell count \\\u003C 75% of the lower limit of normal\n* Concomitant receipt of another cephalosporin interfering with assay\n* Participants likely to require surgical interventions during the study period if the surgery would interfere with dosing intervals or affect sampling process\n* Protected patients; prisoners, patients with HIV, patients with physical or mental disabilities, psychiatric patients.\n* Patients with documented life-threatening allergy (i.e anaphylaxis, angioedema) to any of the study drugs or their class.\n* Patients with conditions known to significantly affect PK; (i.e. severe burn, significant ascites, spinal cord injury and cystic fibrosis)\n* Any other reason felt by the investigators to potentially affect the outcomes of the study",{"count":261,"type":20},200,"The study is aiming to describe the pharmacokinetic and pharmacodynamic profile of intravenous meropenem, ertapenem, cefepime, colistin, Ceftazidime\u002FAvibactam , Ceftolozane\u002FTazobactam , and piperacillin\u002Ftazobactam in the plasma and determine how much is removed by Renal Replacement Therapies to ensure adequate dosing",[28],[265,266,32],"Pharmacokinetics","antibiotics","2023-02-07",{"date":269,"type":42},"2023-02-08",{"date":271,"type":42},"2018-04-01",{"date":273,"type":20},"2026-07-01",{"name":275,"class":49},"Cleveland Clinic Abu Dhabi"]